-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

Benzinga·10/01/2026 14:10:18
Listen to the news
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $32.